Received May 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | X025116 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE/PQC.; first dose was given on 12/07/2024; second dose given on 02/05/2025; third dose given on 03/05/2025; This spontaneous report was received from a pharmacist and refers to a 26-year-old patient of unknown gender. The patient's medical, concurrent conditions and concomitant therapies were not reported. The patient was vaccinated with on 07-DEC-2024 and on 05-FEB-2025 with a first and second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (dose, anatomical location, lot # and expiration date were not reported) respectively for prophylaxis (Inappropriate schedule of product administration). Pharmacist reported that a patient received their third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) prefilled syringe, too early on 05-MAR-2025(lot #X025116, expiration date: 19-MAY-2026), dose: 0.5 mL ( anatomical location was not reported) for prophylaxis (Inappropriate schedule of product administration). Pharmacist reported that the patient was not experiencing any symptoms.